1 / 51

2012/09/27 Combine meeting

2012/09/27 Combine meeting. 58 y/o Female DCMP s/p ECMO s/p DFPP s/p LVAD. 林柑 5305996. Brief History. 2006---DCMP 2008---ICD 2010---Heart transplantation waiting list. 58 yo Female. DCMP with arrhythmia status post permanent pacemaker insertion. 2012/07/07 HsinChu H.:

rance
Télécharger la présentation

2012/09/27 Combine meeting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 2012/09/27 Combine meeting 58 y/o FemaleDCMP s/p ECMO s/p DFPP s/p LVAD 林柑 5305996

  2. Brief History • 2006---DCMP • 2008---ICD • 2010---Heart transplantation waiting list

  3. 58 yo Female DCMP with arrhythmia status post permanent pacemaker insertion. 2012/07/07 HsinChu H.: • unsteady gait and aphasia. Con’s=E4M6Vt • Brain CT: left cerebral subcortical infarction admission 2012/07/07-11: • Progressive dyspnea, oliguria • LVEF=4.6% Pulmonary edema with acute CHF 2012/07/11: Intubation, ECMONTUH

  4. Physical Examination (2012/7/11) Vital Sign: T:36.2 P:64 R:17 BP:108/84 mmHg General appearance: ill Consciousness: E4M6Vt HEENT: grossly normal Eyes: conjunctiva: not pale, sclera: not icteric Pupil Isocoric, light reflex (R/L): +/+, prompt Ears: eardrums not injected. Neck: supple, JVE (-), LAP (-) Chest: symmetric expansion, bil crackles (+), Heart: RHB, no murmur audible Abdomen: soft and flat, no superficial collateral circulations, No tenderness, no rebounding tenderness Bowel sounds: normal active Liver / Spleen: Not palpable Extremities: freely movable, pitting edema (+), cyanosis (-), petechiae (-), rash (-) left femoral ECMO (+)

  5. 2012-7-11 X-ray

  6. 2012/07/12 EKG

  7. 2012/07/16 Cardiac Echo LVEF=14.6% global hypokinesia Moderate MR, TR, PR, Pulmonary Hypertension TRPG=50.7

  8. CAVH on V-A ECMO AKI due to shock related CAVH on ECMO support Waiting for heart transplantation

  9. Lab data Unasyn Tatumcef Donor Crossmatch + 5.4

  10. Cross match  減敏感治療

  11. Desenstitration Order

  12. DFPP Protocol 2A  4A Separator Volume : 1.5 X 30%  10% Extraction Replacement Fluid : Nil

  13. DFPP Course

  14. Treatment Course

  15. Donor Cross match

  16. 問題 • Blood flow ? • Myocardium depression • Fibrinogen consumption • Bleeding • Transfusion • 輸血 • 避免輸血 • 前置作業

  17. Treatment Course in 5CVI 2012/07/14 ECMO+CAVH, on HTx waiting list, PRA(+) 2012/07/25 Start Desensitization Protocol • 7/25 Rituximab 200 mg iv stat with solu-medrol 40 mg st • 7/26 DFPP(2A) with IVIG 7/26, 7/28, 7/30 • 8/1~14 DFPP (4A) with IVIG (QW2,5)  8 courses

  18. Treatment Course in 5CVI • 2012/07/11-8/30: Waiting for Heart Transplantation (ECMO) • ‧Coagulopathy • DFPP + IVIG for desensitization low fibrinogen, bleeding • Thrombus formation s/p emergent evacuation *4 • PRA(+) • VTDC shock (7/29, 8/27,8/28)

  19. 2012/08/30 LVAD implantation OP Method: LVAD THORATEC implantation V cannula: beveled tip against septim through LV apex A cannula: 14mm graft end-to-side anastomosis to AsAo; then wrapped by 20mm Hemashield vascular graft.

  20. Post-OP Course (2012/8/30) 2012/08/30 14:00 • Thoratec blood flow: 6L/min • CVP:24 mmHg, BP:45/42(43) mmHg • Dopamine :9.4 µg/Kg/min Levophed: 1.63 µg/Kg/min, Isuprel : 0.2 µg/Kg/min 2012/08/30 18:00 • BP↓ (48/41mmHg), device alarm: no flow • EKG: bradycardia • Lab: Hyperkalemia(K6.18)with metabolic cidosis (pH=7.05) • s/p correction: BP 169/97, PH 7.546, K 2.90 • Start CVVH

  21. Post-OP Course (2012/8/30) 2012/08/30-31 0:00 • BP drop ↓77/52mmHg VAD alarm(+): poor drainage CVP 27  12  volume challenge! Dop+Isuprel+Levophed+ DC shock*2CPR-> on ECMO

  22. 2012/8/30-31 ABG: lactate↑

  23. Treatment Course in 5CVI 2012/08/31 Pupil dilatation, E1M1Vt BP:50/30mmHg Discuss with family about poor prognosis • 2012/09/02 • Remove ECMO and Thoratec, the pt expired at 11:10AM

  24. 問題 • Blood flow ? • Myocardium depression • Fibrinogen consumption • Bleeding • Transfusion • 輸血 • 避免輸血 • 前置作業

  25. The decrease of patient blood volume was induced by an oncotic pressure drop due to albumin loss and often resulted in a pressure drop.

  26. ECMO + DFPP

  27. Intraoperative plasmapheresis and Cellcept induction • Peri-operative alemtuzumab(Campath-1H) and plasmapheresis for high-PRA positive lymphocyte crossmatch heart transplant: a strategy to shorten left ventricular device support. • Department of surgery, University of Texas Medical Branch, Galveston. • J Heart Lung Transplant. 2008 Sep;27(9): 1036-9. • Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy. • Department of Pediatrics, Washington University school of Medicine. • J Heart Lung Transplant. 2007 Sep;26(9): 876-82. • Pediatric cardiac transplantation in children with high panel reactive antibody. • The Congenital Heart institute of Florida, All children’s Hospital, University of South Florida. • Ann Thorac Surg. 2004 Nov;78(5):1703-9

  28. Protocol • 3-volume exchange in 60-100 min, depending on the patient’s body size. • Repaid removal of calcium and heparin sulfate during pheresis. • The timing of the institution of CPB and pheresis is determined by the expected arrival of the donor heart.

  29. Ann ThoracSurg 2011;92:1428-34

  30. NTUH Plasma exchange during CPB

  31. 移除目標為IgG: 2A或3A (can remove Immunoglobulins while allowing Albumin to be returned) 移除目標為IgM: 4A或5A 移除目標為LDL: 5A (can remove LDL while allowing Albumin and HDL to be returned)

  32. 楊正智order

  33. 楊正智DFPP

  34. 4/18 plasma exchange in OR

  35. LVAD (Thoratec Heartmate VE) • Pulsatile, LV assist Only. • Fixed rate / Chamber filled (asynchrony) • Initiated with flow 2.2L/min/m2, LAP 10-15mmHg • Bridge to Heart Transplantation.

  36. Manual Of Perioperative Care In Adult Cardiac Surgery Ch11 p.479

  37. Contraindication • Reasonable chance of recovery? • Age, medical condition, RV function, • Comorbidities ( neurologic, pulmonary, renal, hepatic) • Other medical issues ( infection, vascular disease, DM…)

  38. Post-LVAD management • Adequate tissue perfusion • Assessed by mixed Venous oxygen saturation • Decrease myocardial demand • Vasoactive medication only for RV function or increased SVR to keep MAP>75mmHg • “vasodilatory shock”

  39. Complication • Mediastinal bleeding, tamponade (60%) • Manifested by inadequate drainage into the device. • Previous coagulopathy, fibrinolysis, plt dysfxn. • Mediastinitis and Sepsis (40-50%) • Device related. • Resistant organism. • Malignant ventricular arrhythmia • LVAD flow↓ • Foster thrombus formation • RV failure (20%)  iNO • Thromboembolism (20%)

  40. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) trial; N=280. • The 1-year survival after LVAD implantation was 56%; in-hospital mortality after LVAD surgery was 27%. • The most important determinants: • poor nutrition • hematological abnormalities • end-organ or right ventricular dysfunction • lack of inotropic support Circulation. 2007 Jul 31;116(5):497-505. Epub 2007 Jul 16

  41. Preoperative RV dysfunction correlated well with postoperative worsening RV dysfunction. • deviation of interventricular septum towards the LV, which eliminates the septal contribution to right heart contractility. Neragi-Miandoab et al. Journal of Cardiothoracic Surgery 2012, 7:60a

  42. Operative mortality of 46% for a score >5. 12% for a scoreto <=5. J ThoracCardiovascSurg 2003;125:855-62

More Related